CDTX - Cidara Therapeutics, Inc.
| Previous Close | 2.9000 |
| Open | 2.9000 |
| Bid | 2.7400 x 1000 |
| Ask | 3.2100 x 2200 |
| Day's Range | 2.7100 - 2.9700 |
| 52 Week Range | 1.2230 - 4.4400 |
| Volume | 162,792 |
| Avg. Volume | 367,695 |
| Market Cap | 115.059M |
| Beta (5Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5330 |
| Earnings Date | Nov 06, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.88 |
- Zacks
Cidara Therapeutics (CDTX) Upgraded to Buy: What Does It Mean for the Stock?
Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences
SAN DIEGO, Feb. 18, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe.
- GlobeNewswire
Cidara Therapeutics Announces Closing of Rights Offering
SAN DIEGO, Feb. 12, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”)..
- Simply Wall St.
Some Cidara Therapeutics (NASDAQ:CDTX) Shareholders Have Taken A Painful 74% Share Price Drop
While not a mind-blowing move, it is good to see that the Cidara Therapeutics, Inc. (NASDAQ:CDTX) share price has...
- GlobeNewswire
Cidara Therapeutics Announces Commencement of Rights Offering
Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on January 21, 2020, of Cidara’s common stock and Series X convertible preferred stock, and Cidara’s warrants issued on May 21, 2018, are entitled to purchase up to 11,952,191 shares of common stock in the aggregate at a subscription price equal to $2.51 per share, or under certain circumstances, shares of non-voting Series X convertible preferred stock in lieu of common stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated January 22, 2020, relating to the Rights Offering.
- Zacks
New Strong Sell Stocks for January 16th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- GlobeNewswire
Cidara Therapeutics Announces Proposed Rights Offering
Under the terms of the rights offering, investors as of January 21, 2020 in Cidara’s common stock and preferred stock, as well as the holders of Cidara’s warrants issued on May 21, 2018, will receive a subscription right entitling them to purchase their pro rata share of the $30.0 million offering amount. The rights offering will be fully backstopped by BVF Partners L.P. and Stonepine Capital, LP, each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed for by other purchasers in the rights offering, for a total of up to $30.0 million.
- Insider Monkey
Hedge Funds Bailed Out Of Cidara Therapeutics Inc (CDTX) Too Early
Does Cidara Therapeutics Inc (NASDAQ:CDTX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]
- Simply Wall St.
Should You Take Comfort From Insider Transactions At Cidara Therapeutics, Inc. (NASDAQ:CDTX)?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- GlobeNewswire
Cidara Therapeutics to Present at Two Upcoming Medical Conferences
SAN DIEGO, Dec. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that.
- GlobeNewswire
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Third Consecutive Year
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the third consecutive year. Cidara was the top life sciences company and only biotech included in the small company category in the San Diego Metro Area. “It is a great honor to be named as one of the best places to work in the San Diego Metro Area for the third consecutive year,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
- GlobeNewswire
Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results
SAN DIEGO, Nov. 07, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported.
- GlobeNewswire
Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will host a Key Opinion Leader (KOL) meeting on its rezafungin and Cloudbreak programs on November 14 in New York City for institutional investors, sell-side analysts, and business development professionals. The meeting will feature presentations from Key Opinion Leaders, Neil J. Clancy, M.D. (University of Pittsburgh), Kieren Marr, M.D. (Johns Hopkins University School of Medicine), and Allison McGeer, M.D. (University of Toronto), who will discuss the unmet medical need in the treatment and prevention of fungal and viral diseases.
- GuruFocus.com
Weekly CFO Buys Highlight
Insiders invested in VBI Vaccines, Cidara Therapeutics and Ocugen Continue reading...
- GlobeNewswire
Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences
SAN DIEGO, Oct. 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that.
- PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
52 Presentations by Coalition Members During the Annual Meeting WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- GlobeNewswire
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 16, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that.
- Benzinga
Wedbush Recommends Buying Cidara Shares After Rezafungin Deal
Cidara Therapeutics Inc (NASDAQ: CDTX ) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin. The Analyst Wedbush analyst Robert Driscoll ...
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Cidara Therapeutics (NASDAQ: CDTX ) shares ...
- Thomson Reuters StreetEvents
Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT
Q3 2017 Cidara Therapeutics Inc Earnings Call
- GlobeNewswire
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
SAN DIEGO, Aug. 08, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported.
- GlobeNewswire
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 10:20 a.m. EDT (7:20 a.m. PDT) in New York City. Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE).
- GlobeNewswire
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline results from Part B of the global Phase 2 STRIVE trial evaluating the company’s lead antifungal candidate rezafungin. In the STRIVE B trial, rezafungin met all of its objectives for efficacy, safety and tolerability in the treatment of patients with candidemia and/or invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly therapy for the first-line treatment and prevention of serious invasive fungal infections.
